|  Home  |  Lunenfeld-Tanenbaum  |  RTC  |  sciHigh  |  Hospital  |  Foundation  |
  Site Map    Contact Us  
Mount Sinai Hospital
Foundation of Toronto - Donate Now campaign
A new finding by Mount Sinai Hospital researchers has the potential to slow the progression of kidney disease, one of the most serious complications for patients with diabetes. Researchers have found a protein associated with kidney disease which potentially can be targeted with drugs in early stages of the disease to prevent end-stage kidney failure.
Published August 13, 2013 in Diabetes, the journal of the American Diabetes Association, the study was led by Dr. George Fantus, an endocrinologist at Mount Sinai Hospital’s Leadership Sinai Centre for Diabetes and a scientist at the Lunenfeld-Tanenbaum Research Institute. The research team discovered that a previously known protein named SRC (pronounced “sark”) is abnormally active in kidney cells that show early signs of this disease. The inappropriately active protein can lead to the build up of scar tissue, which diminishes the kidneys’ filtering ability to eliminate waste and excess fluid from the body.
The findings are especially important for diabetes patients, who are at much higher risk for kidney disease. Over the long term, high blood glucose levels damage tiny blood vessels in the kidney, impairing blood filtration.
“If we can prevent the progression of kidney disease early on, patients who are at risk are potentially saved the long-term burden of chronic kidney dialysis and transplantation,” explains Dr. George Fantus, who is also a Professor with the Departments of Medicine and Physiology at the University of Toronto.
There are currently no effective drug treatments available for patients with kidney disease. The abnormally active protein implicated in this study has previously been linked to cancer, so there are opportunities now to test drugs initially targeted to this protein’s function in tumours in the treatment of kidney disease.
The study was funded in part by the Canadian Institutes of Health Research and the Canadian Diabetes Association.
Quick Facts
·         According to the Canadian Institute for Health Information (CIHI), one in three people with kidney failure has diabetes.
·         According to the Canadian Diabetes Association, about one-third of people who have had diabetes for more than 15 years will develop kidney disease.
·         Kidney failure can also result in substantial costs to the health care system. For example, CIHI’s estimated cost for dialysis treatment is approximately $60,000 per patient, per year of treatment. A one-time cost for a kidney transplant is approximately $23,000 plus $6,000 for necessary annual medication to maintain the transplant.
·         Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute ranks #1 by citations world-wide for diabetes research compared to other medical research institutes.

News and Media


 Ontario Health StudyUofT Fac. Medicinemitacs honorary partner 
Facebook popup Youtube popup Twitter popup RSS popup